Advertisement

Picture EBD Group Biotech Showcase 2019 BTS San Francisco January DIC 600x60px
Document › Details

REPO-TRIAl Project. (5/31/18). "Press Release: REPO-TRIAL – a European Union Project for In Silico Trial-Based Drug Repurposing". Maastricht.

Region Region EU (European Union)
Product Product  business development (state/region)
     


REPO-TRIAL, a 5-year H2020 project funded by a EUR 5.6 million research grant from the European Commission, is gearing up for a huge push towards accelerated rational drug repurposing by using a consistent systems medicine approach combined with advanced in silico discovery technologies. The project commenced on February 1, and is scheduled to conclude on January 31, 2023.

Systems medicine creates an entirely new perspective for pharmaceutical innovation by conceiving the human body not as a modular collection of organs that require separate treatment, but rather as a highly connected network of molecular regulatory pathways. Drug repurposing, a strategy that is enjoying increasing popularity because it provides a quicker and cheaper route to new treatment opportunities, attempts to re-develop known active pharmaceutical ingredients for therapeutic applications that are fundamentally different from the originally envisaged ones.

“The approach that we are testing in REPO-TRIAL has the potential to disrupt medicine and drug development as we know it,” stated REPO-TRIAL project coordinator Professor Harald Schmidt, chair of the Department of Pharmacology and Personalised Medicine at Maastricht University in the Netherlands. “It will allow us to identify opportunities for approved drugs, and also low-dose combinations of such drugs, and to rapidly advance to pilot clinical trials, with minimal requirements for animal experiments. While our focus will be on neurology and cardiology, especially stroke and heart failure, REPO-TRIAL will also look at other areas of high unmet medical need.”

In addition to its ambitious scientific and development goals, REPO-TRIAL is a shining example of collaboration between academia and industry in Europe. Participants include pharmacology and immunology departments from the universities at Maastricht and Utrecht (The Netherlands), the university clinics at Essen and Hannover (Germany), and the bioinformatics departments at Newcastle University (United Kingdom) and the Technical University at Munich (Germany); while industry participants (SomaLogic, United Kingdom), Biocrates (Austria), and H.M. Pharma Consultancy (Austria) will provide invaluable expertise in the fields of biomarkers, patenting, and public dissemination of results.

For addition details please visit the REPO-TRIAL website at http://www.repo-trial.eu.

Interviews with the project coordinator, Prof. Harald Schmidt, can be arranged through the project administrative management office (see below).

Contact:
Magdalena Kosch, concentris research management GmbH
+49 (0)8141 625 285 80
Email: magdalena.kosch@concentris.de


*** ENDS ***

   
Record changed: 2018-07-04

Advertisement

Picture EBD Group Biotech Showcase 2019 BTS San Francisco January DIC 600x60px

To subscribe to our free, monthly mass spectrometry newsletter, please send an e-mail to info@iito.de and simply fill the subject line with the word »MSC Newsletter«

To get even more information, please take a look at our [gs] professional services offering and read the gene-sensor Product Flyer [PDF file]

Please visit also our web portals for the Eurpean life sciences and the life sciences in German-speaking Europe (DE, AT & CH) at Life-Sciences-Germany.com and Life-Sciences-Europe.com

Advertisement

Picture [LSE] Life-Sciences-Europe.com – The Business Web Portal 600x60px




» top